Ireland
--:--IST
Active, not recruiting Observational

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

NCT05062291 · tracked via the Priya Life Science UK tracker
Phase
Observational
Started
2022-06-23
Last updated
2026-10-09

Condition(s) studied

Venous StenosisVenous Occlusion

Investigational drug(s) / intervention(s)

Merit WRAPSODY Endovascular Stent Graft

Merit WRAPSODY Endovascular Stent Graft: Target Lesion Primary Patency (TLPP)

Study summary

The WRAP Study aims to expand and understand the safety and efficacy data on the WRAPSODY Endoprosthesis System in a real-world population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Subject provides written informed consent for study participation. 2. Subject is male or female, with an age ≥ 18 years at date of enrollment. 3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 24 months. 4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon 5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session. 6. Subject has stenosis or occlusion within the dialysis outflow circuit of an arteriovenous (AV) fistula or AV graft and is treated with WRAPSODY Endoprosthesis System in accordance with device instructions for use. Exclusion Criteria: 1. Subject has a planned surgical revision of access site. 2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia. 3. Subject has an uncorrectable coagulation disorder. 4. Known hypersensitivity to nickel titanium alloy. 5. Subject's hemodialysis access is anticipated to be abandoned within 6 months. 6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure. 7. Full expansion of a Percutaneous Transluminal Angioplasty (PTA) balloon cannot be achieved during predilatation. 8. Device would be placed in the Superior Vena Cava 9. Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.

Primary outcome measure(s)

  • Proportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint) — 6 months
    Proportion of subjects with Target Lesion Primary Patency (TLPP) at 6 Months. TLPP is defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or target lesion thrombosis measured through 6 months post-procedure, which is the time interval of uninterrupted patency after study procedure to the next intervention performed on the target lesion or uncorrectable target lesion occlusion.
  • Proportion of subjects without any localized or systemic safety events (Primary Safety Endpoint) — 30 days
    Proportion of subjects without any localized or systemic safety events through 30 days post-index procedure that affect the access or venous outflow circuit and resulted in reintervention, hospitalization, or death (not including stenosis or thrombosis).

Trial sites (35)

FacilityCityRegionStatus
Monash Health Clayton Australia
Liverpool Hospital Liverpool Australia
Fiona Stanley Hospital Murdoch Australia
Sir Charles Gairdner Hospital Nedlands Australia
Princess Alexandra Hospital Woolloongabba Australia
Hospital Felicio Rocho Belo Horizonte Brazil
Afya Hospital Brasília Brazil
Hospital Santa Lucia Brasília Brazil
Hospital Vera Cruz Campinas Brazil
Instituto Pro Renal Curitiba Brazil
Complexo Hospitalar de Niterói Niterói Brazil
Parana Medical Research Center Paranã Brazil
Real Hospital Português de Beneficência em Pernambuco Recife Brazil
Impar Servicos Hospitalares S/A - Hospital Sao Lucas Rio de Janeiro Brazil
Rio de Janeiro State University Rio de Janeiro Brazil
Hospital Da Bahia Salvador Brazil
Centro Internacional de Pesquisa do Hospital Alemão Oswaldo Cruz São Paulo Brazil
Hospital Santa Rita de Cassia São Paulo Brazil
Instituto Dante Pazzanese de Cardiologia São Paulo Brazil
Protestant Hospital Queen Elisabeth Herzberge Berlin Germany
University of Cologne Cologne Germany
The General University Hospital of Patras Rio Greece
Shaare Zedek Medical Center Jerusalem Israel
Maastricht UMC+ Maastricht Netherlands
Te Toka Tumai Auckland Auckland New Zealand
Te Whatu Ora Health NZ Waitemata Auckland New Zealand
Te Whatu Ora Health NZ Waitaha Canterbury Christchurch New Zealand
Te Whatu Ora Health New Zealand Waitemata Hamilton New Zealand
CHUC - Centro Hospitalar e Universitário De Coimbra Coimbra Portugal
Belfast City Hospital, Belfast Health and Social Care Trust Belfast United Kingdom
Queen Elizabeth Hospital, University Hospital Birmingham Birmingham United Kingdom
King's College Hospital, NHS Foundation Trust London United Kingdom
Royal London Hospital, Barts Health NHS Trust London United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom
Royal Berkshire NHS Foundation Trust Reading United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05062291 on ClinicalTrials.gov ↗ ← All trials in the UK